- Home
- NBXG vs BBNX Comparison
NBXG vs BBNX Comparison
Compare NBXG & BBNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | NBXG | BBNX |
|---|---|---|
| Founded | N/A | 2015 |
| Country | United States | United States |
| Employees | N/A | 423 |
| Industry | Trusts Except Educational Religious and Charitable | Medical/Dental Instruments |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 560.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | NBXG | BBNX |
|---|---|---|
| Price | $13.61 | $12.46 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 11 |
| Target Price | N/A | ★ $26.73 |
| AVG Volume (30 Days) | 290.6K | ★ 1.2M |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | $35.03 |
| Revenue Next Year | N/A | $33.24 |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $10.94 | $8.89 |
| 52 Week High | $15.66 | $32.71 |
Technical Indicators
Market Signals| Indicator | NBXG | BBNX |
|---|---|---|
| Relative Strength Index (RSI) | 48.49 | 29.44 |
| Support Level | $13.53 | $12.10 |
| Resistance Level | $13.94 | $15.64 |
| Average True Range (ATR) | 0.28 | 1.02 |
| MACD | 0.06 | 0.30 |
| Stochastic Oscillator | 61.54 | 27.38 |
Price Performance
Historical ComparisonAbout NBXG Neuberger Berman Next Generation Connectivity Fund Inc.
Neuberger Berman Next Generation Connectivity Fund Inc. is a non-diversified, closed-end management investment company. The fund's investment objectives are to provide capital appreciation and income. Under normal market conditions, the Fund will invest at least 80% of its total assets in equity securities issued by U.S. and non-U.S. companies, in any market capitalization range, that is relevant to the theme of investing in NextGen Companies.
About BBNX Beta Bionics Inc.
Beta Bionics Inc is a commercial-stage medical device company engaged in the design, development, and commercialization of solutions to improve the health and quality of life of insulin-requiring people with diabetes (PWD) by utilizing adaptive closed-loop algorithms to simplify and improve the treatment of their disease. The company's product includes the iLet Bionic Pancreas (iLet). The company operates as a single segment, focused on the development, manufacture, and sale of the iLet.